, Volume 20, Issue 2, pp 137–154 | Cite as

The Cephalosporins: Activity and Clinical Use

  • Allan J. Weinstein
Review Article


The cephalosporin antibiotics have been employed with increasing frequency since their introduction into clinical practice in the early 1960s. With the exception of cephaloridine, cephalosporin compounds are not associated with the production of significant untoward effects. The availability of newer cephalosporins, both oral and parenteral, with enhanced antibacterial activity, has expanded the clinical indications for administration of these antibiotics.


Cephalosporin Cefotaxime Bacterial Meningitis Cefoxitin Cephalexin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abraham, E.P.: The cephalosporins. Pharmacological Reviews 14: 473–500 (1971).Google Scholar
  2. Abraham, E.P. and Newton, C.C.F.: New penicillins, cephalosporin C, and penicillinase. Endeavour 20: 92–100 (1961).PubMedGoogle Scholar
  3. Abraham, B.N.; Petz, L.D.; and Fudenberg, H.H.: Immunohaematological cross-allergenicity between penicillin and cephalothin in humans. Clinical and Experimental Immunology 3: 343–357 (1968).PubMedGoogle Scholar
  4. Actor, P.; Pitkin, D.H.; Lucyszyn, G.; Weisbach, J.A. and Bran, J.L.: Cefatrizine (SKF 60771), a new oral cephalosporin: Serum levels and urinary recovery in humans after oral or intramuscular administration — comparative study with cephalexin and cefazolin. Antimicrobial Agents and Chemotherapy 9: 800–803 (1976).PubMedCrossRefGoogle Scholar
  5. Appelstein, J.M.; Crosby, E.B.; Johnson, W.D. and Kaye, D.: In vitro antimicrobial activity and human pharmacology of cephaloglycin. Applied Microbiology 16: 1006–1010 (1968).Google Scholar
  6. Axelrod, J.; Meyers, B.R. and Hirschman, S.Z.: Cephapirin: in vitro antibacterial spectrum. Applied Microbiology 22: 904–908 (1971).PubMedGoogle Scholar
  7. Barza, M.; Tally, F.P.; Jacobus, N.V. and Gorbach, S.L.: In vitro activity of LY127935. Antimicrobial Agents and Chemotherapy 16: 287–292(1979).PubMedCrossRefGoogle Scholar
  8. Bassaris, H.P.; Quintiliani, R.; Maderazo, E.G.; Tilton, R.C. and Nightingale, C.H.: Pharmacokinetics and penetration characteristics of cefazolin into human spinal fluid. Current Therapeutic Research 19: 110–120 (1976).PubMedGoogle Scholar
  9. Batchelor, F.R.; Dewdney, J.M. and Gazzard, D.: Penicillin allergy: The formation of the penicilloyl determinant. Nature (London) 206: 362–364 (1965).CrossRefGoogle Scholar
  10. Bax, R.P.; Dawson, A.F.; Mullinger, B.M. and Dash, C.H.: Cefuroxime in the treatment of lower respiratory tract infection. Current Medical Research and Opinion 5: 772–778 (1979).PubMedCrossRefGoogle Scholar
  11. Berg, S.W.; Kilpatrick, M.E.; Harrison, W.O. and McCutchan, J.A.: Cefoxitin as a single-dose treatment for urethritis caused by penicillinase-producing Neisseria gonorrhoeae. New England Journal of Medicine 301: 509–511 (1979).PubMedCrossRefGoogle Scholar
  12. Bill, N.J. and Washington, J.A. II: Comparison of in vitro activity of cephalexin, cephradine, and cefaclor. Antimicrobial Agents and Chemotherapy 11: 470–474 (1977).PubMedCrossRefGoogle Scholar
  13. Bodey, G.P. and Weaver, S.: In vitro studies of cefamandole. Antimicrobial Agents and Chemotherapy 9: 452–457 (1976).PubMedCrossRefGoogle Scholar
  14. Brandriss, M.W.; Smith, J.W.and Steinman, H.G.: Common antigenic determinants of penicillin G, cephalothin and 6-aminopenicillanic acid in rabbits. Journal of Immunology 94: 696–704 (1965).Google Scholar
  15. Brorson, J.E. and Norrby, R.: Comparative in vitro activity of cefamandole, cefoxitin, cefuroxime and cephalothin. Scandinavian Journal of Infectious Diseases 13 (Suppl.) 88–93 (1978).PubMedGoogle Scholar
  16. Bryant, R.E. and Alford, R.H.: Unsuccessful treatment of staphylococcal endocarditis with cefazolin. Journal of the American Medical Association 237: 569–570 (1977).PubMedCrossRefGoogle Scholar
  17. Buck, R.E. and Price, K.E.: Cefadroxil, a new broad-spectrum cephalosporin. Antimicrobial Agents and Chemotherapy 11: 324–330 (1977).PubMedCrossRefGoogle Scholar
  18. Burdash, N.M.; Ehrlich, M.A.; Ehrlich, H.G. and Parisi, J.T.: Electron microscopy of Proteus vulgaris exposed to cephalothin. Journal of Bacteriology 95: 1956–1960 (1968).PubMedGoogle Scholar
  19. Carrizosa, J.; Levison, M.E. and Kaye, D.: Double-blind controlled comparison of phlebitis produced by cephapirin and cephalothin. Antimicrobial Agents and Chemotherapy 3: 306–307 (1973).PubMedCrossRefGoogle Scholar
  20. Chang, T.W. and Weinstein, L.: In vitro biological activity of cephalothin. Journal of Bacteriology 85: 1022–1027 (1963).PubMedGoogle Scholar
  21. Chang, T.W. and Weinstein, L.: Inhibition of synthesis of the cell wall of Staphylococcus aureus by cephalothin. Science 143: 807–808 (1964a).PubMedCrossRefGoogle Scholar
  22. Chang, T.W. and Weinstein, L.: Morphological changes in Gramnegative bacilli exposed to cephalothin. Journal of Bacteriology 88: 1790–1797 (1964b).PubMedGoogle Scholar
  23. Chisholm, D.R.; Leitner, F.; Misiek, M.; Wright, G.E. and Price, K.D.: Laboratory studies with a new cephalosporanic acid derivative. Antimicrobial Agents and Chemotherapy 244–246 (1969).Google Scholar
  24. Cole, D.R. and Pung, J.: Penetration of cefazolin into pleural fluid. Antimicrobial Agents and Chemotherapy 11: 1033–1035 (1977).PubMedCrossRefGoogle Scholar
  25. Cordero, A.: Treatment of soft tissue infections with cefadroxil, a new oral cephalosporin. Journal of International Medical Research 4: 176–178 (1976).PubMedGoogle Scholar
  26. Cunha, B.A.; Gossling, H.R.; Pasternak, H.S.; Nightingale, C.H. and Quintiliani, R.: The penetration characteristics of cefazolin, cephalothin, and cephradine into bone in patients undergoing total hip replacement. Journal of Bone and Joint Surgery 59A: 856–859(1977).Google Scholar
  27. Cunha, B.A.; Klimek, J.; Nightingale, C. and Quintiliani, R.: Clinical evaluation of cefamandole in lower respiratory and urinary tract infections. Current Therapeutic Research 25: 584–589 (1979).Google Scholar
  28. Currie, J.P.: Cephaloridine: Pharmacology and toxicology. Postgraduate Medical Journal 43 (Suppl.): 22–26 (1967).PubMedGoogle Scholar
  29. Delgado, D.G.; Brau, C.J.; Cobbs, C.G. and Dismukes, W.E.: Clinical and laboratory evaluation of cefamandole in the therapy of Haemophilus species bronchopulmonary infections. Antimicrobial Agents and Chemotherapy 15: 807–812 (1979).PubMedCrossRefGoogle Scholar
  30. Eickhoff, T.C. and Ehret, J.M.: In vitro comparison of cefoxitin, cefamandole, cephalexin, and cephalothin. Antimicrobial Agents and Chemotherapy 9: 994–999 (1976).PubMedCrossRefGoogle Scholar
  31. Fass, R.J. and Prior, R.B.: Comparative in vitro activities of oral cephalosporins and competitive antibiotics against recent clinical isolates. Current Therapeutic Research 24: 352–365 (1978).Google Scholar
  32. Flemming, P.C. and Jaffe, D.: The nephrotoxic effect of cephaloridine. Postgraduate Medical Journal 43 (Suppl): 89–90 (1967).Google Scholar
  33. Friedrich, H.; Pelz, K. and Hansel-Friedrich, G.: Lack of penetration of cephacetril into the cerebrospinal fluid of patients without meningitis. Infection 7: 41–44 (1979).PubMedCrossRefGoogle Scholar
  34. Fu, K.P.; Aswapokee, P.; Ho, I.; Matthijssen, C. and Neu, H.C.: Pharmacokinetics of cefotaxime. Antimicrobial Agents and Chemotherapy 16: 592–597 (1979).PubMedCrossRefGoogle Scholar
  35. Gardner, J.C.; Price, T.M.L. and Southwell, N.: Cephaloridine in the treatment of urmary proteus infections. Lancet 2: 725–727 (1966).PubMedCrossRefGoogle Scholar
  36. Geddes, A.M.; McGhie, D.; Ball, A.P. and Gould, I.: Studies with cefuroxime and cefoxitin. Scandinavian Journal of Infectious Diseases 13 (Suppl.): 78–81 (1978).PubMedGoogle Scholar
  37. Gralnick, H.R. and McGinniss, M.H.: Immune cross-reactivity of penicillin and cephalothin. Nature (London) 216: 1026–1027 (1967).CrossRefGoogle Scholar
  38. Gralnick, H.R.; Wright, L.D. Jr. and McGinniss, M.H.: Coombs’ positive reactions associated with sodium cephalothin therapy. Journal of the American Medical Association 199: 725–726 (1967).PubMedCrossRefGoogle Scholar
  39. Griffith, R.S. and Black, H.R.: Cephalothin — a new antibiotic. Journal of the American Medical Association 189: 823–828 (1964).PubMedCrossRefGoogle Scholar
  40. Griffith, R.S.and Black, H.R.: Cephalexin: A new antibiotic. Clinical Medicine 75: 14–22 (1968).Google Scholar
  41. Henness, D.M.; Richards, D.; Santella, P.J. and Rubinfeld, J.: Oral bioavailability of cefadroxil, a new semisynthetic cephalosporin. Clinical Therapeutics 1: 263–273 (1978).Google Scholar
  42. Inagaki, J. and Bodey, G.P.: Phlebitis associated with cephalosporins: Cephapirin versus cephalothin. Current Therapeutic Research 15: 37–43(1973).PubMedGoogle Scholar
  43. Investigational Manual, LY127935, Eli Lilly and Company, Indianapolis, Indiana, USA (1979).Google Scholar
  44. Johnson, W.D.; Applestein, J.M. and Kaye, D.: Cephaloglycin: Clinical and laboratory experience with an orally administered cephalosporin. Journal of the American Medical Association 206: 2698–2702 (1968).PubMedCrossRefGoogle Scholar
  45. Jones, R.N. and Fuchs, P.C.: Comparison of in vitro antimicrobial activity of cefamandole and cefazolin with cephalothin against over 8,000 clinical bacterial isolates. Antimicrobial Agents and Chemotherapy 9: 1066–1069 (1976).PubMedCrossRefGoogle Scholar
  46. Jones, R.N.; Fuchs, P.C.; Gavan, T.L.; Gerlach, E.H.; Barry, A.L. and Thornsberry, C: Cefuroxime, a new parenteral cephalosporin: collaborative in vitro susceptibility comparison with cephalothin against 5,887 clinical bacterial isolates. Antimicrobial Agents and Chemotherapy 12: 47–50 (1977).PubMedCrossRefGoogle Scholar
  47. Jones, R.N.; Fuchs, P.C.; Thornsberry, C.; Barry, A.L.; Gavan, T.L. and Gerlach, E.H.: Cefaclor and cefatrizine, new investigational orally administered cephalosporins — in vitro collaborative evaluation against clinical bacterial isolates and comparison with related antimicrobics. American Journal of Clinical Pathology 72: 578–585 (1979).PubMedGoogle Scholar
  48. Kabins, S.A. and Cohen, S.: Cephalothin serum levels in the azotemic patient. Antimicrobial Agents and Chemotherapy 4: 207–214 (1964).Google Scholar
  49. Kabins, S.A. and Cohen, S.: Cephaloridine therapy as related to renal function. Antimicrobial Agents and Chemotherapy 5: 922–932 (1965).PubMedGoogle Scholar
  50. Kaiser, G.V.; Gorman, M.and Webber, J.A.: Cefamandole — a review of chemistry and microbiology. Journal of Infectious Diseases 137 (Suppl.): S10–16 (1978).PubMedCrossRefGoogle Scholar
  51. Kammer, R.B. and Short, L.J.: Cefaclor — summary of clinical experience. Postgraduate Medical Journal 55 (Suppl.): 93–97 (1979).PubMedGoogle Scholar
  52. Kaplan, K.; Reisberg, B.E. and Weinstein, L.: Cephaloridine: antimicrobial activity and pharmacologic behavior. American Journal of Medical Sciences 253: 667–674 (1967).CrossRefGoogle Scholar
  53. Klein, J.L.; Eickhoff, T.C.; Tilles, J.G. and Finland, M.: Cephalothin: Activity in vitro, absorption and excretion in normal subjects and clinical observations in 40 patients. American Journal of Medical Sciences 248: 640–656 (1964).CrossRefGoogle Scholar
  54. Klimek, J.J.; Nightingale, C. and Quintiliani, R.: Penetration of cephalosporin antibiotics into human atrial appendage tissue in patients undergoing open-heart surgery (abstract). Sixteenth Interscience Conference on Antimicrobial Agents and Chemotherapy, pp. 27–29 (1976).Google Scholar
  55. Knusel, F.; Konopka, E.A.; Geizer, J. and Rosselet, A.: Antimicrobial studies in vitro with CIBA 36278-Ba, a new cephalosporin derivative. Antimicrobial Agents and Chemotherapy 140–149 (1970).Google Scholar
  56. Kunin, C.M. and Brandt, D.: Comparative studies of ampicillin, cephalothin and a new cephalosporin derivative, cephaloglycin. American Journal of Medical Sciences 255: 196–201 (1968).CrossRefGoogle Scholar
  57. Lambin, S. and Bernard, J.: Mode of action in vitro of cephaloridine against Staphylococcus aureus and Escherichia coli. Postgraduate Medical Journal 43 (Suppl.): 42–46 (1967).PubMedGoogle Scholar
  58. Landes, R.R.; McCormick, B.; Graham, R.; Melnick, I. and Brown, D.: Cephaloridine therapy for genitourinary infections. Southern Medical Association 60: 311–316 (1967).Google Scholar
  59. Levinson, M.E.; Johnson, W.D.; Thornhill, T.S. and Kaye, D.: Clinical and in vitro evaluation of cephalexin. Journal of the American Medical Association 209: 1331–1336 (1969).CrossRefGoogle Scholar
  60. Levison, M.E.; Santoro, J. and Agarwal, B.N.: In vitro activity and pharmacokinetics of cefaclor in normal volunteers and patients with renal failure. Postgraduate Medical Journal 55 (Suppl. 4): 12–16 (1979).PubMedGoogle Scholar
  61. Lode, H.; Stahlmann, R. and Koeppe, P.: Comparative pharmacokinetics of cephalexin, cefaclor, cefadroxil, and CGP 9000. Antimicrobial Agents and Chemotherapy 16: 1–6 (1979).PubMedCrossRefGoogle Scholar
  62. Low, R.A.L. and Clarke, T.K.: Cephradine in urinary tract infections: A double-blind comparison with ampicillin. Current Medical Research and Opinion 3: 211–217 (1975).PubMedCrossRefGoogle Scholar
  63. Luthy, R.; Munch, R.; Blaser, J.; Bhend, H. and Siegenthaler, W.: Human pharmacology of cefotaxime (HR 756), a new cephalosporin. Antimicrobial Agents and Chemotherapy 16: 127–133 (1979).PubMedCrossRefGoogle Scholar
  64. Mangi, R.J., Kundargi, R.S.; Quintiliani, R. and Andriole, V.T.: Development of meningitis during cephalothin therapy. Annals of Internal Medicine 78: 347–351 (1973).PubMedGoogle Scholar
  65. Meyers, B.R.; Kaplan, K. and Weinstein, L.: Cephalexin: Microbiological effects and pharmacologic parameters in man. Clinical Pharmacology and Therapeutics 10: 810–816 (1969).PubMedGoogle Scholar
  66. Meyers, B.R.; Leng, B. and Hirschman, S.Z.: Cefamandole: Antimicrobial activity in vitro of a new cephalosporin. Antimicrobial Agents and Chemotherapy 8: 737–741 (1975).PubMedCrossRefGoogle Scholar
  67. Mirrett, S. and Relier, L.B.: Comparative activity in vitro of cefaclor, cephalexin, and cephradine. Current Therapeutic Research 26: 145–151 (1979).Google Scholar
  68. Moellering, R.C., Jr.: Cefamandole — a new member of the cephalosporin family. Journal of Infectious Diseases 137 (Suppl.): S2–S9 (1978).PubMedCrossRefGoogle Scholar
  69. Moellering, R.C., Jr. and Swartz, M.N.: The newer cephalosporins. New England Journal of Medicine 294: 24–28 (1976).PubMedCrossRefGoogle Scholar
  70. Molthan, L.; Reidenberg, M.M. and Eichman, M.F.: Positive direct Coombs’ tests due to cephalothin. New England Journal of Medicine 277: 123–125 (1967).PubMedCrossRefGoogle Scholar
  71. Mouallem, R.: Comparative efficacy and safety of cephradine and cephalexin in children. Journal of International Medical Research 4: 265–271 (1976).PubMedGoogle Scholar
  72. Muggleton, P.W.; O’Callaghan, C.H.; Foord, R.D.; Kirby, S.M. and Ryan, D.M.: Laboratory appraisal of cephalexin. Antimicrobial Agents and Chemotherapy A 353–360 (1968).Google Scholar
  73. Neu, H.C.: Comparison of the pharmacokinetics of cefamandole and other cephalosporin compounds. Journal of Infectious Diseases 137 (Suppl.): S80–S87 (1978).PubMedCrossRefGoogle Scholar
  74. Neu, H.C.; Aswapokee, N.; Fu, K.P. and Aswapokee, P.: Antibacterial activity of a new 1 -oxa cephalosporin compared with that of other β-lactam compounds. Antimicrobial Agents and Chemotherapy 16: 141–149 (1979a).PubMedCrossRefGoogle Scholar
  75. Neu, H.C.; Fu, K.P.; Aswapokee, N.; Aswapokee, P. and Kung, K.: Comparative activity and β-lactamase stability of cefoperazone, a piperazine cephalosporin. Antimicrobial Agents and Chemotherapy 16: 150–157 (1979b).PubMedCrossRefGoogle Scholar
  76. Neu, H.C. and Winshell, E.B.: In vitro evaluation of cephacetrile, a new cephalosporin antibiotic. Journal of Antibiotics 25: 400–404 (1972).PubMedCrossRefGoogle Scholar
  77. Nightingale, C.H.; Greene, D.S. and Quintiliani, R.: Pharmacokinetics and clinical use of cephalosporin antibiotics. Journal of Pharmaceutical Sciences 64: 1899–1927 (1975).PubMedCrossRefGoogle Scholar
  78. Oller, L.Z.: Cephaloridine in gonorrhoeae and syphilis. British Journal of Venereal Diseases 43: 39–47 (1967a).Google Scholar
  79. Oller, L.Z.: Cephaloridine in early syphilis. Postgraduate Medical Journal 43 (Suppl.): 128–129 (1967b).PubMedGoogle Scholar
  80. Parker, C.W.: Penicillin allergy. American Journal of Medicine 34: 747–749 (1963).PubMedCrossRefGoogle Scholar
  81. Parry, M.F.; Goldberger, M.J. and Neu, H.C.: Therapy of serious infections with cefamandole. Infection 6: 236–240 (1978).PubMedCrossRefGoogle Scholar
  82. Perkins, R.L.; Apicella, M.A.; Lee, I.; Cuppage, F.E. and Saslaw, S.: Cephaloridine and cephalothin: Comparative studies of potential nephrotoxicity. Journal of Laboratory and Clinical Medicine 71: 75–84 (1968).PubMedGoogle Scholar
  83. Perkins, R.L.; Saslaw, S. and Hackett, J.: Cephaloridine and cephalothin comparative in vitro evaluation. American Journal of Medical Sciences 253: 293–299 (1967).CrossRefGoogle Scholar
  84. Perkins, R.L.; Slama, T.G.; Fass, R.J.; Prior, R.B.; Plouffe, J.F.; Warner, J.F. and File, T.M.: Therapy of skin, soft tissue, and bone infections with cefoxitin sodium. Review of Infectious Diseases 1: 165–169 (1979).CrossRefGoogle Scholar
  85. Phillips, I.; King, A.; Warren, C. and Watts, B.: The activity of penicillin and eight cephalosporins on Neisseria gonorrhoeae. Journal of Antimicrobial Therapy 2: 31–39 (1976).CrossRefGoogle Scholar
  86. Pitt, J.; Siasoco, R.; Kaplan, K. and Weinstein, L.: Antimicrobial activity and pharmacological behavior of cephaloglycin. Antimicrobial Agents and Chemotherapy 630–635 (1967).Google Scholar
  87. Quinn, E.L.; Pohloh, D.; Madhavan, T.; Burck, K.; Fisher, E. and Cox, F.: Clinical experience with cefazolin and other cephalosporins in bacterial endocarditis. Journal of Infectious Diseases 128 (Suppl.): 386–391 (1973).CrossRefGoogle Scholar
  88. Quintiliani, R. and Nightingale, C.H.: Diagnosis and treatment: Drugs five years later —cefazolin. Annals of Internal Medicine 89: 650–656 (1978).PubMedGoogle Scholar
  89. Rahal, J.J., Jr.; Meyers, B.R. and Weinstein, L.: Treatment of bacterial endocarditis with cephalothin. New England Journal of Medicine 279: 1305–1309 (1968).PubMedCrossRefGoogle Scholar
  90. Ratzan, K.R.; Ruiz, C. and Irvin, G.L.: Biliary tract excretion of cefazolin, cephalothin, and cephaloridine in the presence of biliary tract disease. Antimicrobial Agents and Chemotherapy 6: 462–431 (1974).CrossRefGoogle Scholar
  91. Regamey, C.; Libke, R.D.; Engelking, E.R.; Clarke, J.T. and Kirby, W.M.M.: Inactivation of cefazolin, cephaloridine, and cephalothin by methicillin-sensitive and methicillin-resistant strains of Staphylococcus aureus. Journal of Infectious Diseases 131: 291–294 (1975).PubMedCrossRefGoogle Scholar
  92. Ribner, B.S.; Billiard, B.S. and Freimer, E.H.: Clinical evaluation of cefatrizine in 101 patients. Current Therapeutic Research 24: 614–621 (1978).Google Scholar
  93. Ribner, B.S.; Billiard, B.S. and Freimer, E.H.: Treatment of significant bacterial infections in adults with cefoxitin. Reviews of Infectious Diseases 1: 152–157 (1979).PubMedCrossRefGoogle Scholar
  94. Robson, H.G. and Bowmer, M.I.: Treatment of pneumonia and other serious bacterial infections with cephapirin. Antimicrobial Agents and Chemotherapy 6: 274–281 (1974).PubMedCrossRefGoogle Scholar
  95. Sanders, W.E., Jr.; Johnson, J.E., III. and Taggart, J.G.: Adverse reactions to cephalothin and cephapirin. Uniform occurrence on prolonged intravenous administration of high doses. New England Journal of Medicine 290: 424–429 (1974).PubMedCrossRefGoogle Scholar
  96. Santella, P.J.; Tanrisever, B. and Berman, E.: An overview of results of world-wide clinical trials with cefadroxil. Journal of International Medical Research 6: 441–451 (1978).PubMedGoogle Scholar
  97. Scholand, J.F.; Hodges, G.R.; Fass, R.J. and Saslaw, S.: Clinical evaluation of cephradine, a new oral cephalosporin. American Journal of Medical Sciences 267: 111–116 (1974).CrossRefGoogle Scholar
  98. Schrogie, J.J.; Davies, R.O.; Yeh, K.C.; Rogers, D.; Holmes, G.I.; Skeggs, H. and Martin, C.M.: Bioavailability and pharmacokinetics of cefoxitin sodium. Journal of Antimicrobial Chemotherapy 4 (Suppl. B): 69–78 (1978).PubMedGoogle Scholar
  99. Seneca, H.; Lattimer, J.K.; Reilly, M. and Peer, P.: Cephalothin in cystoscopy and retrograde pyelography. Journal of Urology 94: 489–491 (1965).PubMedGoogle Scholar
  100. Seneca, H.; Peer, P. and Warren, B.: Treatment of urinary tract infections with cephaloridine. Journal of Urology 97: 154–155 (1967).Google Scholar
  101. Shadomy, S.; Wagner, G. and Carver, M.: In vitro activities of five oral cephalosporins against aerobic pathogenic bacteria. Antimicrobial Agents and Chemotherapy 12: 609–613 (1977).PubMedCrossRefGoogle Scholar
  102. Shemonsky, N.K.; Carrizosa, J. and Levison, M.E.: In vitro activity and pharmacokinetics in patients of cefamandole, a new cephalosporin antibiotic. Antimicrobial Agents and Chemotherapy 8: 679–683(1975).PubMedCrossRefGoogle Scholar
  103. Sheng, K.T.; Huang, N.N. and Promadhattavedi, V.: Serum concentrations of cephalothin in infants and children and placental transmissions of the antibiotic. Antimicrobial Agents and Chemotherapy 200–206 (1964).Google Scholar
  104. Siegel, M.S.; Thompson, S.E.; Perine, P.L.; Brown, S.T.; Reynolds, G. and Thornsberry, C.: Treatment of uncomplicated gonococcal urethritis with cefoxitin: Comparison with penicillin. Reviews of Infectious Diseases 1: 183–187 (1979).PubMedCrossRefGoogle Scholar
  105. Silver, M.S.; Counts, G.W.; Zeleznik, D. and Turck, M.: Comparison of in vitro antibacterial activity of three oral cephalosporins: Cefaclor, cephalexin, and cephradine. Antimicrobial Agents and Chemotherapy 12: 591–596 (1977).PubMedCrossRefGoogle Scholar
  106. Simon, H.J.; Axline, S.G. and Vosti, K.L.: Cephalothin. Its in vitro antibacterial spectrum as studied in a diagnostic laboratory. California Medicine 103: 395–399 (1965).PubMedGoogle Scholar
  107. Sosna, J.P.; Murray, P.R. and Medoff, G.: Comparison of the in vitro activities of HR 756 with cephalothin, cefoxitin, and cefamandole. Antimicrobial Agents and Chemotherapy 14: 876–879 (1978).PubMedCrossRefGoogle Scholar
  108. Southern, P.M., Jr. and Sanford, J.P.: Meningococcal meningitis — suboptimal response to cephalothin therapy. New England Journal of Medicine 280: 1163–1165 (1969).PubMedCrossRefGoogle Scholar
  109. Stapley, E.O.; Birnbaum, J.; Miller, A.K.; Wallick, H.; Hendlin, D. and Woodruff, H.B.: Cefoxitin and cephamycins: Microbiological studies. Reviews of Infectious Diseases 1: 73–87 (1979).PubMedCrossRefGoogle Scholar
  110. Stewart, G.T.: Cross allergenicity of penicillin G and related substances. Lancet 1: 509–510 (1962).PubMedCrossRefGoogle Scholar
  111. VanLanduyt, H.W. and Pyckavet, M.: In vitro activity of cefotaxime against cephalothin-resistant clinical isolates. Antimicrobial Agents and Chemotherapy 16: 109–111 (1979).CrossRefGoogle Scholar
  112. VanWinzum, C.: Clinical safety and tolerance of cefoxitin sodium: An overview. Journal of Antimicrobial Chemotherapy 4 (Suppi. B): 91–104 (1978).PubMedGoogle Scholar
  113. Waterman, N.G.; Eickenberg, H.U. and Scharfenberger, L.: Concentration of cefamandole in serum interstitial fluid, bile, and urine. Antimicrobial Agents and Chemotherapy 10: 733–735-(1976).PubMedCrossRefGoogle Scholar
  114. Webb, D.; Thadepalli, H. and Bach, V.: Cefoxitin therapy for bacterial endocarditis. Reviews of Infectious Diseases 1: 170–174 (1979).PubMedCrossRefGoogle Scholar
  115. Weinstein, L.: The cephalosporins: Microbiological, chemical, and pharmacological properties and use in chemotherapy of infection. Annals of Internal Medicine 72: 729–739 (1970).PubMedGoogle Scholar
  116. Weinstein, L.: Panel discussion of severe Gram-positive infections. Postgraduate Medical Journal 47 (Suppl. Feb): 94–102 (1971).PubMedGoogle Scholar
  117. Weinstein, M.P. and Eickhoff, T.C.: Clinical evaluation of cefoxitin in the treatment of respiratory tract and other acute bacterial infections. Reviews of Infectious Diseases 1: 158–164 (1979).PubMedCrossRefGoogle Scholar
  118. Wick, W.E.: Influence of antibiotic stability on the results of in vitro testing procedures. Journal of Bacteriology 87: 1162–1170 (1964).PubMedGoogle Scholar
  119. Wick, W.E.: Cephalexin, a new orally absorbed cephalosporin antibiotic. Applied Microbiology 15: 765–769 (1967).PubMedGoogle Scholar
  120. Wiesner, P.; MacGregor, R.; Bear, D.; Berman, S.; Holmes, K. and Turck, M.: Evaluation of a new cephalosporin antibiotic, cephapirin. Antimicrobial Agents and Chemotherapy 1: 303–309 (1972).PubMedCrossRefGoogle Scholar
  121. Windorfer, A. and Gasteiger, U.: Studies on serum and cerebrospinal fluid levels of cephacetrile in neonates. Infection 5: 242–247 (1977).PubMedCrossRefGoogle Scholar
  122. Wise, R.; Andrews, J.M. and Bedford, K.A.: LY127935, a novel oxa-β-lactam: An in vitro comparison with other β-lactam antibiotics. Antimicrobial Agents and Chemotherapy 16: 341–345 (1979).PubMedCrossRefGoogle Scholar

Copyright information

© ADIS Press Australasia Pty Ltd 1980

Authors and Affiliations

  • Allan J. Weinstein
    • 1
  1. 1.Department of Infectious DiseaseCleveland Clinic FoundationClevelandUSA

Personalised recommendations